Vivint Pharma to invest Rs 400 crores in new injectables facility at Genome Valley

NEW YORK: Vivint Pharma, an injectables pharmaceutical company, announced plans to establish a state-of-the-art injectables manufacturing facility in Genome Valley, Hyderabad. The company committed to investing Rs 400 crores in the new facility, which has the potential to employ 1,000 people, further solidifying Telangana’s position as a global hub for life sciences.

The announcement was made during a high-level meeting in the United States with Chief Minister A Revanth Reddy and Minister for Industries and Commerce D. Sridhar Babu. This significant investment underscored Vivint Pharma's commitment to expanding its footprint in India, particularly Telangana, which has emerged as a preferred destination for pharmaceutical and biotechnology companies.

Vivint Pharma already had an R&D centre in Genome Valley and had invested about Rs 70 crores in the facility. To consolidate its strengths and foray into international markets, the company has decided to establish its first manufacturing plant and acquired 5.5 acres in Genome Valley, known for its world-class infrastructure and conducive ecosystem for research, innovation, and manufacturing.

Revanth Reddy expressed his delight, stating, "I am delighted to note Vivint Pharma’s investment in Genome Valley. Telangana has always been at the forefront of fostering innovation in the life sciences sector, and this investment will add further impetus."

Sridhar Babu also expressed his enthusiasm, stating, "This investment is a testament to the business-friendly environment nurtured by our Government. Genome Valley continues to be a magnet for pharmaceutical companies, and Vivint Pharma’s decision to set up a new manufacturing facility here reaffirms our leadership in the life sciences domain."

Vivint Pharma’s injectables facility will focus on developing and producing high-quality injectable drugs in the oncology and critical care space for both domestic and international markets. The company’s decision to invest in Genome Valley aligned with its strategy to leverage India’s skilled workforce and the region’s advanced manufacturing capabilities to meet the growing global demand for pharmaceutical products.